Buscofenact 12 Tablets 400 Gr

€9.90
Tax included
Minsan
041631021
100% secure payments
Hurry up! Only 5 item(s) left in Stock!
Quantity

WARNINGS
Undesirable effects can be minimized with the use of the lowest effective dose for the shortest possible duration of treatment necessary to achieve symptom control. Caution is warranted in patients with certain clinical conditions, which may worsen: patients with systemic lupus erythematosus and various connective tissue disorders have an increased risk of developing aseptic meningitis; congenital pathology of porphyrin metabolism; gastrointestinal pathologies and chronic intestinal inflammatory pathologies; hypertension and / or cardiac impairment as renal function may worsen; renal impairment; liver failure; immediately after major surgeries; in patients who have allergic reactions to other substances, since for such patients there is a greater risk of hypersensitivity reactions also following the use of Ibuprofen; in patients suffering from hay fever, nasal polyps or chronic obstructive airway diseases as there is an increased risk of allergic reactions for such patients. These reactions may present as asthma attacks (so-called analgesic asthma), Quincke's edema or urticaria. Gastrointestinal Effects: The use of Ibuprofen in combination with other NSAIDs increases the risk of adverse reactions and should be avoided. Elderly: have a higher frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal. Gastrointestinal bleeding, ulceration or perforation: Gastrointestinal bleeding, ulceration or perforation, sometimes fatal, has been reported at any stage of treatment with the use of all NSAIDs, with or without prodromal symptoms or a previous history of gastrointestinal events. If gastrointestinal bleeding or ulceration occurs in patients taking ibuprofen, treatment should be discontinued. The risk of gastrointestinal bleeding, ulceration or perforation increases with higher doses of NSAIDs, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation, and in elderly patients. These patients should start treatment with the lowest available dose. Concomitant therapy with protective agents should be considered for these patients and also for patients taking concomitantly low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events. Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding), especially in the initial stages of treatment. Caution should be exercised in patients on concomitant treatment with drugs that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as their condition may worsen. Skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. Patients appear to be at increased risk for these reactions early in therapy; in fact, in most cases, the reaction occurs in the first month of treatment. The administration of Ibuprofen must be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity '. Exceptionally, chickenpox can be at the origin of serious skin infections and complications affecting the soft tissues. Until now, it has not been possible to exclude that NSAIDs contribute to the worsening of these infections. It is therefore recommended not to use Ibuprofen in the course of chickenpox. Cardiovascular and cerebrovascular effects: caution is required before starting treatment in patients with a history of hypertension and / or heart failure, as fluid retention, hypertension and edema have been reported in association with NSAID therapy. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and / or cerebrovascular disease should only be treated with ibuprofen after careful consideration. Similar considerations should be made before initiating long-term treatment in patients with risk factors for cardiovascular disease. Clinical studies and epidemiological data suggest that the use of ibuprofen, especially at high doses (2400 mg per day) and for long-term treatments, it may be associated with a modest increased risk of arterial thrombotic events. Overall, epidemiological studies do not suggest that low-dose ibuprofen (eg <= 1200 mg per day) is associated with an increased risk of myocardial infarction. Very rarely severe acute hypersensitivity reactions have been observed. At the first signs of a hypersensitivity reaction following the intake / administration of Ibuprofen, the therapy should be discontinued. The required medical measures must be carried out by experienced personnel. Ibuprofen can temporarily inhibit platelet function (platelet aggregation). Therefore, patients with platelet disorders should be carefully monitored. In case of prolonged treatment with ibuprofen, it is necessary to regularly check the liver and kidney parameters, as well as the blood picture. Prolonged use of any pain reliever for headache can make it worse. If this occurs or is suspected, discontinue treatment. The diagnosis of drug overuse headache (MOH) should be suspected in patients with frequent or daily headaches despite (or because of) the regular use of headache medications. In general, the habitual use of analgesics, in particular the combination of different analgesic active ingredients, can lead to permanent renal lesions with the risk of renal failure (analgesic nephropathy). This risk may be increased under physical exertion associated with salt loss and dehydration. Therefore this must be avoided. In case of concomitant alcohol intake during NSAID use, adverse events related to the active substance, especially those affecting the gastrointestinal tract or central nervous system, may increase. Ibuprofen contains sorbitol.
PHARMACOTHERAPEUTIC CATEGORY
Non-steroidal anti-inflammatory and antirheumatic drugs.
STORAGE
This medicinal product does not require any special storage temperatures.
CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity 'to ibuprofen or to any of the excipients; history of hypersensitivity '(eg. bronchospasm, asthma, rhinitis, angioedema or urticaria) associated with the intake of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs); haematological disorders of unknown origin; history of recurrent or ongoing peptic ulcer / haemorrhage (two or more distinct episodes of proven ulceration or bleeding); history of gastrointestinal bleeding or perforation related to previous NSAID therapy; cerebrovascular haemorrhage or other bleeding episodes; severe liver failure, severe kidney failure or severe heart failure; third trimester of pregnancy; adolescents with body weight below 40 kg and children; patients with severe dehydration (due to vomiting, diarrhea or insufficient fluid intake).
NAME
IBUPROFENE BOEHRINGER INGELHEIM 400 MG SOFT CAPSULES
EXCIPIENTS
Capsule contents: macrogol 600, potassium hydroxide, purified water. Capsule shell: gelatin, liquid sorbitol, purified water. >> Printing ink. Ingredients of Opacode WB black NS-78-17821: black iron oxide (E172), propylene glycol (E1520), hypromellose 6cP.
SIDE EFFECTS
The reported frequencies, which occur with incidence higher than very rare cases, refer to the short-term use of daily doses up to a maximum of 1200 mg of ibuprofen for the oral dosage form and a maximum of 1800 mg for suppositories. . It should be taken into account that the following undesirable effects are basically dose-dependent and vary from individual to individual. Clinical studies and epidemiological data suggest that the use of ibuprofen, especially at high doses (2400 mg per day) and for long-term treatment, may be associated with a slightly increased risk of arterial thrombotic events (eg. myocardial infarction or stroke). Patients should be advised to stop taking Ibuprofen immediately if a serious adverse reaction occurs. Adverse reactions are listed below by system organ class, and by frequency, according to the following categories: very common (> = 1/10); common (> = 1/100, <1/10); uncommon (> = 1/1000, <1/100); rare (> = 1 / 10,000, <1/1000); very rare (1 / 10,000); not known. Infections and infestations. Very rare: Worsening of infectious inflammations (eg development of necrotizing fasciitis) has been observed in conjunction with the use of non-steroidal anti-inflammatory drugs. This is probably associated with the mechanism of action of non-steroidal anti-inflammatory drugs. Symptoms of aseptic meningitis with neck stiffness, headache, nausea, vomiting, fever or clouding of consciousness have been observed during treatment with ibuprofen. Patients with autoimmune diseases (SLE, mixed connective tissue disease) appear to be predisposed. Disorders of the blood and lymphatic system. Very rare: haematopoietic disorders (anemia, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis). The first signs may be: fever, sore throat, superficial sores in the mouth, flu-like symptoms, severe fatigue, nosebleeds and skin bleeding. In long-term therapy, blood counts should be checked regularly. Disorders of the immune system. Uncommon: hypersensitivity reactions' with skin rashes, and itching, asthma attacks (with possible drop in blood pressure); very rare: severe generalized hypersensitivity reactions, the signs of which may be facial edema, swelling of the tongue, swelling of the larynx with constriction of the respiratory tract, respiratory distress, tachycardia, drop in blood pressure, up to life-threatening shock. If any of these symptoms occur, and this can happen even on first use, immediate medical attention is required. Psychiatric disorders. Very rare: psychotic reactions, depression. Nervous system disorders. Uncommon: central nervous system disorders, such as headache, dizziness, insomnia, agitation, irritability or fatigue. Eye disorders. Uncommon: visual disturbances. Ear and labyrinth disorders. Rare: tinnitus. Cardiac pathologies. Very rare: palpitations, heart failure, myocardial infarction. Vascular pathologies. Very rare: arterial hypertension. Gastrointestinal disorders. Common: gastrointestinal disorders, such as heartburn, abdominal pain, nausea, vomiting, flatulence, diarrhea, constipation, slight gastrointestinal blood loss which in exceptional cases lead to anemia; uncommon: gastrointestinal ulcer with potential for haemorrhage and perforation. Ulcerative stomatitis, worsening of colitis and Crohn's disease, gastritis; very rare: esophagitis, pancreatitis, formation of diaphragmatic intestinal strictures. If you feel severe pain in the upper abdomen or if melaena or haematemesis occurs, you are advised to inform your doctor immediately and stop taking the medicine. Hepatobiliary disorders. Very rare: hepatic dysfunction, liver damage, especially in case of prolonged therapy, hepatic failure, acute hepatitis. Skin and subcutaneous tissue disorders. Very rare: Bullous reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, alopecia. In exceptional cases, severe skin and soft tissue infections can occur in the course of chickenpox infection. Renal and urinary disorders. Rare: damage to kidney tissue (papillary necrosis) and high concentrations of uric acid in the blood may also be observed rarely; very rare: formation of edema, especially in patients with arterial hypertension or renal insufficiency, nephrotic syndrome, interstitial nephritis, which may be accompanied by acute renal insufficiency. Kidney function should be checked regularly. If necessary, patients should be adequately advised to discontinue Ibuprofen treatment if any of the following occur: severe gastrointestinal upset, heartburn or abdominal pain; hematemesis; melaena or blood in the urine; skin reactions, such as itchy rashes; respiratory distress and / or edema of the face or larynx; fatigue associated with loss of appetite; sore throat, associated with aphthous ulcers, fatigue and fever; severe nosebleeds and skin bleeding; abnormal fatigue associated with reduced urinary excretion; edema in the feet or legs; chest pain.
PREGNANCY AND BREASTFEEDING
Inhibition of prostaglandin synthesis can adversely affect pregnancy and / or embryo / fetal development. Results of epidemiological studies raise concerns about an increased risk of spontaneous abortion, cardiac malformations and gastroschisis following the use of a prostaglandin synthesis inhibitor in early pregnancy. The risk is believed to increase with increasing dose and duration of therapy. In animals, the administration of a prostaglandin synthesis inhibitor resulted in an increase in pre- and post-implantation loss and in embryo-fetal mortality. Furthermore, an increase in the incidence of malformations, including cardiovascular, has been reported in animals treated with a prostaglandin synthesis inhibitor during the period of organogenesis. During the first and second trimester of pregnancy, ibuprofen should be administered only in case of absolute necessity '. If ibuprofen is used in women intending to conceive or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment should be as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to the risk of: cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension); renal dysfunction, which can worsen up to renal failure with oligo-hydroamniosis. At the end of pregnancy, the mother and the newborn to: possible prolongation of the bleeding time, an antiplatelet effect which can occur even at very low doses; inhibition of uterine contractions which can lead to a delay or prolongation of labor at the time of delivery. Consequently, the administration of ibuprofen is contraindicated during the third trimester of pregnancy. Ibuprofen and its metabolites can pass in low concentrations into breast milk. To date, no deleterious effects on infants are known. Therefore, for short-term treatment of pain and fever at the recommended dose, it should generally not be necessary to stop breastfeeding. There is some evidence that drugs that inhibit cyclo-oxygenase / prostaglandin synthesis may impair female fertility by acting on ovulation. Once the treatment with ibuprofen has ended, the effect is reversible.
INDICATIONS
Symptomatic treatment of: mild to moderate pain such as headache, toothache and menstrual pain; fever and pain associated with the common cold; indicated in adults and adolescents with a body weight greater than 40 kg (age 'equal to or greater than 12 years).
INTERACTIONS
>> Concomitant use of ibuprofen. Other NSAIDs, including salicylates: concomitant administration of several NSAIDs may increase the risk of gastrointestinal bleeding and ulcers due to a synergistic effect. Consequently, the concomitant use of ibuprofen with other NSAIDs should be avoided. Digoxin: the concomitant use of Ibuprofen with drugs containing digoxin, can 'increase the serum levels of the latter. Usually, if digoxin is used correctly (for up to 4 days) it is not necessary to check its serum levels. Corticosteroids: These may increase the risk of adverse reactions, particularly of the gastrointestinal tract (gastrointestinal bleeding or ulceration). Antiplatelet agents: increased risk of gastrointestinal bleeding. Acetylsalicylic acid (low dose): Experimental data suggest that ibuprofen may inhibit the low dose effect of acetylsalicylic acid on platelet aggregation when the two drugs are administered simultaneously. However, the limitations of these data and the uncertainties regarding the extrapolation of the ex vivo data and their applicability to clinical situations do not allow definitive conclusions to be drawn about the regular use of ibuprofen and no clinically relevant effect is considered likely later occasional use of ibuprofen. Anticoagulants: NSAIDs can increase the effects of anticoagulants, such as coltsfoot. Phenytoin: the concomitant use of Ibuprofen and phenytoin-based preparations can 'increase the serum levels of these medicines. Usually, if used correctly (for up to 4 days) it is not necessary to check the serum levels of phenytoin. Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding. Lithium: the concomitant use of Ibuprofen with lithium preparations may increase the serum levels of these drugs. Usually, if used correctly (for up to 4 days) it is not necessary to check the serum lithium levels. Probenecid and sulfinpyrazone: drugs containing probenecid and sulfinpyrazone can delay the elimination of ibuprofen. Diuretics, ACE inhibitors, beta-blockers and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with impaired renal function (especially dehydrated patients or elderly patients with impaired renal function) the co-administration of an ACE inhibitor, a beta-blocker or angiotensin II antagonists and agents that inhibit cyclo-oxygenase may lead to further worsening of renal function, including possible acute renal failure, usually reversible. Therefore, these combinations should be administered with caution especially in elderly patients. Patients should be adequately hydrated and renal function monitoring should be considered at the initiation of concomitant therapy and on a periodic basis thereafter. Potassium-sparing diuretics: The concomitant intake of ibuprofen and potassium-sparing diuretics can lead to hyperkalaemia (a serum potassium check is recommended). Methotrexate: ibuprofen administered in the 24 hours before or after taking methotrexate can increase its concentrations and therefore toxicity. Ciclosporins: the risk of cyclosporine-induced kidney damage may be increased by the concomitant use of some NSAIDs. This effect cannot be ruled out in case of concomitant use of cyclosporine and ibuprofen. Tacrolimus: the risk of nephrotoxicity increases in case of concomitant administration of ibuprofen and tacrolimus. Zidovudine: When ibuprofen and zidovudine are co-administered, there is evidence of an increased risk of haemarthroses and bruising in HIV-positive haemophiliacs. Sulfonylureas: Clinical research has shown that there are interactions between non-steroidal anti-inflammatory drugs and antidiabetic drugs (sulphonylureas). Although interactions between ibuprofen and sulphonylureas have not been described so far, it is advisable to monitor blood glucose in case of concomitant use of these two drugs. Quinolone antibiotics: Animal studies indicate that NSAIDs may increase the risk of seizures associated with the use of quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures.
DOSAGE
Adults and adolescents with a body weight> 40 kg (aged 12 years or more): 400 mg of ibuprofen. If necessary, an additional 400 mg dose of ibuprofen can be taken. The interval between doses should be established based on the symptoms observed and the maximum recommended daily dose, and should not be less than 6 hours. Do not take more than 1200 mg of ibuprofen in 24 hours. For short-term treatments only. If Ibuprofen is to be taken for more 'than 3 days in case of fever or for more than 4 days for pain treatment or if symptoms worsen, the patient is advised to consult a doctor. It is recommended to take it on a full stomach for people with gastric disorders. If taken shortly after eating, the onset of Ibuprofen's effect may be delayed. If this happens do not take Ibuprofen more 'than recommended or until the correct interval between doses has elapsed. Elderly: no special dosage adjustments are required. Due to possible side effects, elderly subjects should be carefully monitored. Renal insufficiency: no special dosage adjustments are required. Hepatic impairment: No special dose adjustments are required in patients with mild or moderate hepatic impairment. Pediatric population: Ibuprofen is contraindicated in adolescents with a body weight below 40 kg and in children due to the high content of the active ingredient. Method of administration: for oral use. The soft capsules should not be chewed.
ACTIVE PRINCIPLES
Ibuprofen.
041631021
5 Items

Specific References

chat Comments (0)
No customer reviews for the moment.

Buscofenact 12 Tablets 400 Gr

€9.90